Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Ni Chroinin, Muireann ^a   Lasserson, Toby J ^b   Greenstone, Ilana ^c   Ducharme, Francine M ^d  

^a University College Cork and INFANT Centre   (Ireland)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; FORMOTEROL; PLACEBO; SALMETEROL; STEROID;

ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; LUNG FUNCTION; MONOTHERAPY; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 70049098581     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007949     Document Type: Review

References (157)

1. Akpinarli A, Tuncer A, Saraclar Y, Sekerel BE, Kalayci O. Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial. Archives of Disease in Childhood 1999;81(1):45-48 (Pubitemid 29307455)
2. Barnes PJ, O'Byrne PM, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A. Oxis and Pulmicort turbuhaler in the management of asthma OPTIMA international study group. Treatment ofmild persistent asthma with low doses of inhaled Budesonide alone or in combination with Formoterol. Thorax 2000;55 (Suppl 3):A4.
3. Barnes PJ, O'Byrne PM, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. For the Oxis and Pulmicort Turbuhaler in the Management of Asthma (OPTIMA) international study group. Thorax 2000; Vol.55, issue Suppl 3:s5.
4. Bisgaard H, Hultquist C. Budesonide/formoterol for maintenance and as needed - a new approach to asthma management in children [Abstract]. European Respiratory Journal 2005;26(Suppl 49):Abstract No. 1060.
5. * Bisgaard H, Le Roux P, Bjamer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy - a new strategy in pediatric asthma. Chest 2006;130(6):1733-1743
6. Jönsson BG, Berggren FE, Svensson K, O'Byrne PM. Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide - a cost-effectiveness analysis. European Respiratory Journal. 2001; Vol.18, issue Suppl 33:517s.
7. Jönsson BG, Berggren FE, Svensson K, O'Byrne PM. Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal 2001; Vol.18, issue Suppl 33:331s.
8. O'Byrne PM. Acute asthma intervention: Insights from the STAY study. Journal of Allergy & Clinical Immunology 2007;119(6):1332-1336
9. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Sandtröm T, Tattersfield AE, Runnerström EM, Svensson K. Addition of formoterol Turbuhaler® to budesonide Tubuhaler® is safe and well tolerated in the long-term treatment of mild asthma: results from the OPTIMA trial.. European Respiratory Journal 2001; Vol.18, issue Suppl 33: 330s.
10. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, Ekstrom T, Bateman ED. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.[see comment]. American Journal of Respiratory & Critical Care Medicine 2005;171(2):129-136
11. SD-039-0673. Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler® as Single Therapy in patients with mild-moderate asthma. Comparison with Symbicort Turbuhaler and Pulmicort® Turbuhaler as maintenance therapy, both complemented with Bricanyl® Turbuhaler (STAY). http: //www.astrazenecaclinicaltrials.com 2006.
12. Heuck C, Heickendorff L, Wolthers OD. A randomized controlled trial of short term growth and collagen turnover in asthmatics with inhaled formoterol and budesonide. Archives of Disease of Childhood 2000;83(4):334-339 (Pubitemid 30744776)
13. Heuck C, Heickendorff L, Wolthers OD, Sygehus S. Short term growth and collagen turnover in asthmatics treated inhaled formoterol and budesonide. European Respiratory Society; Oct 9-13; Madrid, Spain. 1999. 1999:364.
14. Langton Hewer S, Hobbs J, French D, Lenney W. Pilgrims progress: the effect of salmeterol in older children with chronic severe asthma. Respiratory Medicine 1995;89(6):435-440
15. Dorinsky P, Emmett A, Sutton L. Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs ICS alone [Abstract]. European Respiratory Journal 2004;24(Suppl 48):308s.
16. House K, Dorinsky PM, Stauffer J, Schoaf L, Ellsworth A. The Safety of Fluticasone propionate/Salmeterol Diskus(R) in Pediatric Patients Ages 4 -11 with Asthma [Abstract]. Chest 2004;126(Suppl 4):911S.
17. * Malone R, LaForce C, Nimmagadda S, Schoaf L, House K, Ellsworth A, Dorinsky P. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Annals of Allergy, Asthma, & Immunology 2005;95 (1):66-71.
18. SAS30031. A Randomized, Double-Blind, 12-Week Trial Evaluating the Safety of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID Versus Fluticasone Propionate DISKUS 100mcg BID in Symptomatic Pediatric Subjects (4-11 Years) With Asthma. http://www.ctr.gsk.co.uk 2005.
19. Scott C, Wu W, Ellsworth A, Crim C. Efficacy and safety of fluticasone propionate/salmeterol DISKUS and fluticasone propionate DISKUS and HFA in children [Abstract]. European Respiratory Journal 2005;26(Suppl 49):Abstract No. 1057.
20. Meijer GG, Postma DS,Mulder PG, van Aalderen WM. Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids. American Journal of Respiratory & Critical Care Medicine 1995;152:1887-1892
21. AstraZeneca. A 12-week randomised, double-blind, parallel-group, multicentre phase-III study to compare the efficacy and safety of Symbicort® pMDI (budesonide/formoterol 80/4.5 mcg 2 actuations b.i.d., delivered dose) with that of Pulmicort® pMDI (budesonide 100 mcg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler® (budesonide/formoterol 80/4.5 mcg 2 actuations b.i.d., delivered dose) in children with asthma. http: //www.astrazenecaclinicaltrials.com (accessed 4th January 2008) 2007.
22. * Morice AH, Peterson S, Beckman O, Kukova Z. Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/ formoterol in children with asthma: A superiority and therapeutic equivalence study. Pulmonology Pharmacology Therapeutics 2008;21(1):152-159
23. AstraZeneca. A 12-week randomised, double-blind, parallel-group, multicentre phase-III study to compare the efficacy and safety of Symbicort® pMDI (budesonide/formoterol 80/4.5 mcg 2 actuations b.i.d., delivered dose) with that of Pulmicort® pMDI (budesonide 100 mcg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler® (budesonide/formoterol 80/4.5 mcg 2 actuations b.i.d., delivered dose) in children with asthma. http: //www.astrazenecaclinicaltrials.com (accessed 4th January 2008) 2007.
24. * Morice AH, Peterson S, Beckman O, Kukova Z. Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/ formoterol in children with asthma: A superiority and therapeutic equivalence study. Pulmonology Pharmacology Therapeutics 2008; Vol.21, issue 1:152-159
25. Ortega-Cisnero M, Maldonado-Alaniz ML, Rosas Vargas MA, Sierra-Monge JJL. Salmeterol and inhaled beclomethasone versus high dose inhaled beclomethasone in the control of pediatric patients with moderate asthma. Annals of Allergy, Asthma and Immunology 1998; 80:131.
26. Pohunek P, Kuna P, De Boeck K. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma [Abstract]. European Respiratory Journal 2004;24(Suppl 48): 379s.
27. * Pohunek P, Kuna P, Jorup C, Boeck KD. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatric Allergy and Immunology 2006;17(6):458-465
28. Pohunek P, Matulka M, Rybnicek O, Kopriva F, Honomichlova H, Svobodova T. Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Pediatric Allergy & Immunology 2004;15(1):32-39 (Pubitemid 38327297)
29. Pohunek P, Kuna P, De Boeck K. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma [Abstract]. European Respiratory Journal 2004;24(Suppl 48): 379s.
30. * Pohunek P, Kuna P, Jorup C, Boeck KD. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatric Allergy and Immunology 2006;17(6):458-465
31. Pohunek P, Matulka M, Rybnicek O, Kopriva F, Honomichlova H, Svobodova T. Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Pediatric Allergy & Immunology 2004;15(1):32-39 (Pubitemid 38327297)
32. Glaxo Smith Kline (SALMP/AH91/D89). A phase III,multi-centre, double-blind, placebo controlled, parallel group study assessing the efficacy and safety of inhaled salmeterol xinafoate (Serevent™) 50 micrograms BDvia the Diskhaler™when added to the existing treatment of moderate to severe asthmatic children. www.ctr.gsk.co.uk (accessed 9th June 2008) 2006.
33. * Russell G, Williams DAJ, Weller P, Price JF. Salmeterol xinafoate on children on high dose inhaled steroids. Annals of Allergy, Asthma and Immunology 1995;75:423-428
34. Glaxo Smith Kline (SAM104926). A multicentre, randomised, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination (SERETIDE™) at a dose of 50/100mcg twice daily and fluticasone propionate (FLIXOTIDE™) at a dose of 200mcg twice daily, both delivered via a dry powder inhaler (DISKUS™) for 12 weeks in asthma in children aged 4-11 years not controlled by inhaled corticosteroids alone at medium dose. http://ctr.gsk.co.uk (accessed 14/01/2008) 2007.
35. Dorinsky P, Emmett A, Sutton L. Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) versus ICS alone [Abstract]. European Respiratory Journal 2004;24(Suppl 48):308s.
36. * Glasxo Smith Kline (SAM40012). A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate (SFC) (50/100mcg strength) bd via DISKUS/ACCUHALERinhaler, 2) fluticasone propionate 200mcg bd via DISKUS/ACCUHALER inhaler, 3) fluticasone propionate 100mcg bd via DISKUS/ACCUHALER inhaler in children aged 4-11 years with asthma. http://www.ctr.gsk.co.uk 2005.
37. Dorinsky P, Emmett A, Sutton L. Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs ICS alone [Abstract]. European Respiratory Journal 2004;24(Suppl 48):308s.
38. * Glaxo Smith Kline (SAM40012). A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate (SFC) (50/100mcg strength) bd via DISKUS/ACCUHALERinhaler, 2) fluticasone propionate 200mcg bd via DISKUS/ACCUHALER inhaler, 3) fluticasone propionate 100mcg bd via DISKUS/ACCUHALER inhaler in children aged 4-11 years with asthma. http://www.ctr.gsk.co.uk 2005.
39. Glaxo Smith Kline (SAM40100). Randomised, double-blind, comparator study to demonstrate the superiority of salmeterol/fluticasone propionate combination DISKUS™50/100mcg bd over fluticasone propionate DISKUS™/ ACCUHALER™ 200mcg bd with respect to airway physiology in asthmatic children treated for 6 weeks. http: //ctr.gsk.co.uk (accessed 4th January 2008) 2006.
40. AstraZeneca Pharmaceuticals (SD 039 0714). Efficacy and safety of budesonide/formoterol Turbuhaler® (160/4.5 mcg b.i.d. delivered dose) compared to budesonide Turbuhaler® (200mcg b.i.d. metered dose) in steroid-using asthmatic adolescent patients. A double-blind, double-dummy, randomised, parallel group, phase III, multicentre study. http://www. astrazenecaclinicaltrials.com 2005:[Accessed 21-02/2006].
41. AstraZeneca Pharmaceuticals (SD 039 0718). A twelve-week, randomized, double-blind, double-dummy trial of Symbicort® (40/4.5 mcg) versus its mono-products (budesonide and formoterol) in asthmatic children aged six to fifteen years. http: //www.astrazenecaclinicaltrials.com (accessed 4th January 2008) 2005.
42. AstraZeneca Pharmaceuticals (SD 039 0719). A six-month, randomized, open-label safety study of Symbicort® (160/4.5mcg) compared to Pulmicort Turbuhaler® in asthmatic children aged 6 to 11 years. http://www. astrazenecaclinicaltrials.com(accessed 4th January 2008) 2005.
43. AstraZeneca Pharmaceuticals (SD 039 0725). A twelve-week, randomized, double-blind, double-dummy, active-controlled study of Symbicort® pMDI administered once daily in children and adolescents 6 to 15 years of age with asthma. http: //www.astrazenecaclinicaltrials.com (accessed 4th January 2008) 2005.
44. AstraZeneca Pharmaceuticals (SD 039 0725). A twelve-week, randomized, double-blind, double-dummy, active-controlled study of Symbicort® pMDI administered once daily in children and adolescents 6 to 15 years of age with asthma. http://www.astrazenecaclinicaltrials.com 2005:(accessed 4th January 2008).
45. Glaxo Smith Kline (SFA100314). A stratified, multicenter, randomized, double-blind, parallel group, 4-week comparison of fluticasone propionate/salmeterol DISKUS combination product 100/50mcg BID versus fluticasone propionate DISKUS 100mcg BID in pediatric and in adolescent subjects with activity-induced bronchospasm. http://www.ctr.gsk.co.uk (accessed 16th May 2008) 2007.
46. Glaxo Smith Kline (SFA100316). A stratified, multicenter, randomized, double-blind, parallel group, 4-week comparison of fluticasone propionate/salmeterol DISKUS combination product 100/50mcg BID versus fluticasone propionate DISKUS 100mcg BID in pediatric and in adolescent subjects with activity-induced bronchospasm. http://ctr.gsk.co.uk (accessed 30th April 2008) 2006.
47. Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997;99(5):655-659
48. * Stelmach I, Grzelewskia T, Bobrowska-Korzeniowska M, Stelmach P, Kuna P. A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma. Pulmonology Pharmacology & Therapeutics 2007;20:691-700.
49. AstraZeneca Pharmaceuticals (SD 039 0353). Efficacy and safety of budesonide/formoterol Turbuhaler® in a fixed combination in steroid-using asthmatic children. http: //www.astrazenecaclinicaltrials.com (accessed 25th April 2008).
50. Tal A, Simon G, Vermeulen JH. Symbicort® (Budesonide and formoterol in a single inhaler) is effective and well tolerated in children with asthma. Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23. 2001.
51. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, de Boeck C, Jerre F. Symbicort (budesonide and formoterol in a single inhaler) improves lung function in children with asthma. International Paediatric Respiratory and Allergy Congress, April 1-4; Prague. 2001:85.
52. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, de Boeck C, Jerre F. Symbicort (budesonide and formoterol in a single inhaler) is more effective that budesonide alone in children with asthma. International Paediatric Respiratory and Allergy Congress April 1-4; Prague. 2001:84-85
53. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, De Boeck C, Naya I. Rapid and sustained improvements in lung function and symptom control with budesonide/ formoterol in adolescent asthma. European Respiratory Journal 2001; Vol.18, issue Suppl 33:494s.
54. * Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, de Boeck K. Budesonide/Formoterol in a single Inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric Pulmonology 2002;34(5):342-350
55. Vermeulen JH, Simon G, Tal A. Symbicort® (Budesonide and formoterol in a single inhaler) improves lung function in asthmatic children aged 4-17 years. Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23. 2001.
56. Teper AM, Zaragoza SM, Lubovich S, Rodriguez VA, Venalago C, Kofman CD Vidauretta SM. Effect of fluticasone propionate (FP) with or without salmeterol (S) on bronchial reactivity (BR) in children with mild to moderate persistent asthma [Abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego, California. 2005:[C47] [Poster: A5].
57. Verberne AAPH, Frost C, Duiverman EJ, Grol MH, Kerribijn KF. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. American Journal of Respiratory & Critical Care Medicine 1998;158(1):213-219 (Pubitemid 28337183)
58. Verberne AAPH, Frost C, Duiverman EJ, Grol MH, Kerribijn KF. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. American Journal of Respiratory & Critical Care Medicine 1998;158:213-219 (Pubitemid 28337183)
59. * Zimmerman B, D'Urzo A, Berube D. Efficacy and safety of formoterol turbuhaler(R) when added to inhaled corticosteroid treatment in children with asthma. Pediatric Pulmonology 2004;37(2): 122-127
60. Zimmerman B, D'Urzo A, Berube D. Efficacy and tolerability of formoterol turbuhaler(r) compared with placebo, in children (6-11 yr) with asthma poorly controlled with inhaled corticosteroids [abstract]. American Journal of Respiratory and Critical Care Medicine 2002;165(8 Suppl):A746.
61. Zimmerman B, D'Urzo A, Berube D. Efficacy and tolerability of formoterol Turbuhaler in 6-11 year old children with asthma, not adequately controlled with inhaled corticosteroids. European Respiratory Society Annual Congress. 2002:P2734.
62. * Zimmerman B, D'Urzo A, Berube D. Efficacy and safety of formoterol turbuhaler(R) when added to inhaled corticosteroid treatment in children with asthma. Pediatric Pulmonology 2004;37(2): 122-127
63. Zimmerman B, D'Urzo A, Berube D. Efficacy and tolerability of formoterol turbuhaler(r) compared with placebo, in children (6-11 yr) with asthma poorly controlled with inhaled corticosteroids [abstract]. American Journal of Respiratory and Critical Care Medicine 2002;165(8 Suppl):A746.
64. Zimmerman B, D'Urzo A, Berube D. Efficacy and tolerability of formoterol Turbuhaler in 6-11 year old children with asthma, not adequately controlled with inhaled corticosteroids. European Respiratory Society Annual Congress. 2002:P2734.
65. Aldington S, Williams M, Weatherall M, Beasley R. Duration of action of the salmeterol/fluticasone combination inhaler administered in the evening: A randomized controlled trial in childhood asthma. Respirology 2006;11(5):638-642 (Pubitemid 44186272)
66. Aubier M, Pieters WR, Schlosser NJ, Steinmetz KO. Salmeterol/ fluticasone propionate (50/500 mug) in combination in a Diskus(TM) inhaler (Seretide(TM)) is effective and safe in the treatment of steroid-dependent asthma. Respiratory Medicine 1999;93 (12):876-884 (Pubitemid 30042638)
67. Bergmann KC, Lindemann L, Braun R, Steinkamp G. Salmeterol/ fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma. Swiss Medical Weekly 2004;134(3-4):50-58 (Pubitemid 38139882)
68. Borker R, Emmett A, Jhingran P, Rickard K, Dorinsky P. Determining economic feasibility of fluticasone propionate-salmeterol vsmontelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves. Annals of Allergy, Asthma, & Immunology 2005;95(2):181-189 (Pubitemid 41170180)
69. Boulet LP, Roberts J, Watson EG. Efficacy of salmeterol/fluticasone propionate MDI versus higher dose fluticasone propionate in adolescent and adult asthmatics uncontrolled on fluticasone propionate alone [Abstract]. European Respiratory Journal 2003;22(Suppl 45): Abstract No: [P2799].
70. Bousquet J, Gaugris S, Kocevar VS, Zhang Q, Yin DD, Polos PG, Bjermer L. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: A subgroup analysis of the improving asthma control trial. Clinical & Experimental Allergy 2005;35(6):723-727 (Pubitemid 40961343)
71. Bracamonte T, Schauer U, Emeryk A, Godwood A, Balsara S. Efficacy and safety of salmeterol/fluticasone propionate combination delivered by the Diskus or pressurised metered-dose inhaler in children with asthma. Clinical Drug Investigation 2005;25(1):1-11. (Pubitemid 40070108)
72. Bruce SA, Scherer YK. Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations. Evidence-Based Nursing 2005 Jul;8(3):78.
73. Bruggenjurgen B, Selim D, Kardos P, Richter K, Vogelmeier C, Roll S, et al.Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma. Pharmacoeconomics 2005;23(7):723-731 (Pubitemid 41003077)
74. Buchvald FF, Bisgaard H. Comparison of add-on of leukotriene receptor antagonist vs. long-acting beta 2-agonist of FeNO in asthmatic children on regular inhaled budesonide. European Respiratory Journal 2002;20(Suppl 38):431s.
75. Buhl R, Kardos P, Richter K, Meyer-Sabellek W, Bruggenjurgen B, Willich SN, Vogelmeier C. The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing. Current Medical Research & Opinion 2004;20(8):1209-1220 (Pubitemid 39120785)
76. Caffey LF, Raissy HH, Marshik P, Kelly HW. A crossover comparison of fluticasone propionate and montelukast on inflammatory indices in children with asthma. Pediatric Asthma Allergy & Immunology 2005;18(3):123-130 (Pubitemid 41324874)
77. Chopra N, Williams M, Rimmer M, Kahl L, Jenkins M, SMO30006 and SMO30007 International Study Teams. Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma. Respiratory Medicine 2005;99(SUPPL 1):S1-S10.
78. Chuchalin A, Kasl M, Bengtsson T, Nihlen U, Rosenborg J. Formoterol used as needed in patients with intermittent or mild persistent asthma. Respiratory Medicine 2005;99(4):461-470 (Pubitemid 40347830)
79. Cowan S, Ernst P, Cartier A, Boulet LP. A population-based evaluation of a regional asthma education centre. Canadian Respiratory Journal 2004;11(1):39-44. (Pubitemid 38401256)
80. Daviskas E, Anderson SD, Shaw J, Eberl S, Seale JP, Yang IA, Young IH. Mucociliary clearance in patients with chronic asthma: effects of beta agonists. Respirology 2005;10(4):426-435 (Pubitemid 43942610)
81. Delaronde S, Peruccio DL, Bauer BJ. Improving asthma treatment in a managed care population. American Journal of Managed Care 2005;11(6):361-368 (Pubitemid 40875305)
82. Dubus J C, Mely L, Huiart L, Marguet C, Le Roux P, Reseau de Recherche Clinique en Pneumologie Pediatrique. Cough after inhalation of corticosteroids delivered from spacer devices in children with asthma.. Fundamental & Clinical Pharmacology 2003;17(5): 627-631
83. Emeryk A, Bracamonte T, Schauer U, Balsara S, Athisegaran R. Efficacy of salmeterol/fluticasone propionate (50/100mcg/day) delivered via the Diskus and MDi in children with asthma [Abstract]. European Respiratory Journal 2003;22(Suppl 45):Abstract No: [P1985].
84. Everden P, Campbell M, Harnden C, McGoldrick H, Bodalia B, Manion V, Reynia S. Eformoterol Turbohaler compared with salmeterol by dry powder inhaler in asthmatic children not controlled on inhaled corticosteroids.. Pediatric Allergy & Immunology 2004;15(1): 40-47 (Pubitemid 38327298)
85. Fardon TC, Lee DK, Hodge MR, Lipworth BJ. Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma. Annals of Allergy, Asthma, & Immunology 2005;95(3):259-265
86. Grady J, Dockhorn R, Blake K. Effects of inhaled salmeterol powder in adult and adolescent asthmatics using concurrent inhaled corticosteroids [abstract]. European Respiratory Journal. Supplement. 1995; 8 Suppl 19:2S.
87. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, et al.Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clinical & Experimental Allergy 2004;34(4):632-638 (Pubitemid 38534897)
88. Holt S, Ryder-Lewis S, Masoli M, Weatherall M, Beasley R. Fixed and adjustable dose asthma action plans based on combination therapy: a pilot study. Respirology 2005;10(4):497-503. (Pubitemid 43942620)
89. Ilowite J, Webb R, Friedman B, Kerwin E, Bird SR, Hustad CM, Edelman JM. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Annals of Allergy, Asthma, & Immunology 2004; 92(6):641-648 (Pubitemid 39243154)
90. Jenkins CR, Thien FCK, Wheatley JR, Reddel HK. Traditional and patient-centred outcomes with three classes of asthma medication. European Respiratory Journal 2005;26(1):36-44.
91. Karaman O, Arli O, Uzuner N, Islekel H, Babayigit A, Olmez D, et al.The effectiveness of asthma therapy alternatives and evaluating the effectivity of asthma therapy by interleukin-13 and interferon gamma levels in children. Allergy & Asthma Proceedings 2007;28(2): 204-209
92. Lara-Perez EA. Emprovement of the asthma in children using salmeterol and fluticasone (Seretide) in inhaled combination [Abstract]. XIX World Allergy Organization Congress. 2005:Abstract 861.
93. Levy R, Pinnas J, Milgrom H, Smith J, Yegen U. Safety and efficacy in children with persistent asthma treated with formoterol 10 mug BID delivered via Certihaler: A novel multidose dry-powder inhaler. Pediatric Asthma Allergy & Immunology 2005;18(1):25-35. (Pubitemid 40548275)
94. American Lung Association Asthma Clinical Research. Randomized comparison of strategies for reducing treatment in mild persistent asthma. New England Journal of Medicine 2007;356(20):2027-2039
95. Matthys H, Behling B, Behling E. Comparison of formoterol (12 and 6 mug b.i.d) versus terbutaline (0.5 mg b.i.d) with equal doses of inhaled budesonide (0.2 mg bid) in 246 children with mild to moderate asthma. Atemwegs- Und Lungenkrankheiten 2004;30(5): 251-256 (Pubitemid 38787448)
96. Miraglia del Giudice M, Capristo M, Amelio R, Rocco A, Fusco N, Brunese FP. Combined fluticasone propionate/salmeterol (diskus) vs fluticasone propionate (Diskus) in the control of persistent asthma in children. American Thoracic Society 99th International Conference. 2003:A117 Poster D78.
97. * Miraglia del Giudice M, Piacentini GL, Capasso M, Capristo C, Maiello N, Boner AL, Capristo AF. Formoterol, montelukast, and budesonide in asthmatic children: Effect on lung function and exhaled nitric oxide. Respiratory Medicine 2007;101(8):1809-1813
98. Mitchell EA, Didsbury PB, Kruithof N, Robinson E, Milmine M, Barry M, Newman J. A randomized controlled trial of an asthma clinical pathway for children in general practice. Acta Paediatrica 2005;94(2):226-233 (Pubitemid 40343700)
99. Mitra A, Sims EJ, Mukhopadhyay S, Lipworth BJ. Low-dose inhaled corticosteroid (ICS) confers optimal anti-inflammatory effects while additional bronchodilator activity is afforded by salmeterol in mild persistent asthmatic children [Abstract]. Journal of Allergy and Clinical Immunology 2003;111(2 Suppl):S145.
100. Morice AH, Hochmuth L, Puterman A, Artheden L, Beckman O. Comparable safety of a novel budesonide/formoterol pMDI versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma [Abstract]. Journal of Allergy & Clinical Immunology 2005; 115(2 Suppl):S3.
101. Morice AH, Osmanliev D, Arheden L, Beckman O. Therapeutic equivalence of a novel budesonide/formoterol pMDI versus budesonide/ formoterol Turbuhaler in adolescents and adults with asthma [Abstract]. Journal of Allergy & Clinical Immunology 2005;115(2 Suppl):S2.
102. Murray J, Rosenthal R, Somerville L, Blake K, House K, Baitinger L, Vander Meer A, Dorinsky P. Fluticasone propionate and salmeterol administered viaDiskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. Annals of Allergy, Asthma, & Immunology 2004;93 (4):351-359 (Pubitemid 39382976)
103. Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E, et al.Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest 2005;128(4):1910-1920 (Pubitemid 41507521)
104. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15-26.
105. Nguyen WT, Stewart C, Fisher K, Tolley E, Lew Db, Self Th. Maintenance Asthma Treatment With Fluticasone/Salmeterol Combination Via Diskus: Effect on Outcomes in Inner-City Children Enrolled in Tenncare. Allergy and Asthma Proceedings 2005;26(2):129-134 (Pubitemid 40770075)
106. Barnes PJ, O'Byrne PM, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A. Oxis and Pulmicort turbuhaler in the management of asthma OPTIMA international study group. Treatment ofmild persistent asthma with low doses of inhaled Budesonide alone or in combination with Formoterol. Thorax 2000;55 (Suppl 3):A4.
107. Barnes PJ, O'Byrne PM, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. For the Oxis and Pulmicort Turbuhaler in the Management of Asthma (OPTIMA) international study group. Thorax 2000; Vol.55, issue Suppl 3:s5.
108. Bisgaard H, Hultquist C. Budesonide/formoterol for maintenance and as needed - a new approach to asthma management in children [Abstract]. European Respiratory Journal 2005;26(Suppl 49):Abstract No. 1060.
109. Jönsson BG, Berggren FE, Svensson K, O'Byrne PM. Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide - a cost-effectiveness analysis. European Respiratory Journal. 2001; Vol.18, issue Suppl 33:517s.
110. Jönsson BG, Berggren FE, Svensson K, O'Byrne PM. Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal 2001; Vol.18, issue Suppl 33:331s.
111. * O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A. Low dose inhaled budesonide and formoterol in mild persistent asthma: The OPTIMA randomized trial. American Journal of Respiratory & Critical Care Medicine 2001;164(8 pt 1):1392-1397
112. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Sandtröm T, Tattersfield AE, Runnerström EM, Svensson K. Addition of formoterol Turbuhaler ® to budesonide Tubuhaler® is safe and well tolerated in the long-term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal 2001; Vol.18, issue Suppl 33: 330s.
113. Pearlman DS, Peden D, Condemi JJ, Weinstein S, White M, Baitinger L, Scott C, Ho S-Y, House K, Dorinsky P. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma. Journal of Asthma 2004;41(8):797-806. (Pubitemid 40019131)
114. Peroni DG, Piacentini GL, Bodini A, Ress M, Costella S, Boner AL. Montelukast versus formoterol as second-line therapy in asthmatic children exposed to relevant allergens. Allergy & Asthma Proceedings 2005;26(4):283-286 (Pubitemid 41381403)
115. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: A randomized controlled trial. American Journal of Respiratory & Critical Care Medicine 2005;172(7):831-836
116. Prieto L, Gutierrez V, Perez-Frances C, Badiola C, Lanuza A, Bruno L, Ferrer A. Effect of fluticasone propionate-salmeterol therapy on seasonal changes in airway responsiveness and exhaled nitric oxide levels in patients with pollen-induced asthma. Annals of Allergy, Asthma, & Immunology 2005;95(5):452-461 (Pubitemid 41688507)
117. Renzi PM, Frassen E, Stat P, Watson EG. Salmeterol/fluticasone propionate diskus (ADVAIR) 50/100mcg bid improves asthma outcomes compared with fluticasone propionate (FLOVENT) diskus 100mcg bid when used as initial maintenance treatment in adult and adolescent subjects with symptomatic persistent asthma [Abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego, California. 2005:[C33] [Poster: F65].
118. SAM30002 (GSK). A randomised, double blind, double-dummy, parallel-group, twelve week comparison of salmeterol/fluticasone propionate (FP) DISKUS/ACCUHALER 50/100mcg bd. with budesonide 200mcg bd. plus formoterol 4.5mcg bd. (both by breath-activated dry powder inhaler [BADPI]) in adult and adolescent asthmatics. Www.Clinicalstudyresults.Org 2004.
119. Glaxo Smith Kline. A pilot single centre, randomised, double-blind, crossover study to demonstrate the superiority of Salmeterol/ fluticasone propionate combination product 50/100mcg bd versus fluticasone propionate 100mcg bd when treated for two weeks with respect to activity levels in children aged 7-15 years. http: //ctr.gsk.co.uk (accessed 4th January 2008) 2006.
120. * SAS30021. A Stratified, randomized, double-blind, placebo-controlled, parallel-group, 12-week trial evaluating the safety and efficacy of the fluticasone propionate/salmeterol DISKUS combination product 100/50mcg once daily versus fluticasone propionate DISKUS 100mcg once daily and placebo in symptomatic pediatric subjects (4-11 years) with asthma. http://www.ctr.gsk.co.uk 2005: Accessed 28th April 2008.
121. Schauer U, Bracamonte T, Emeryk A, Balsara S, Athisegaran R. Clinincal equivalence of salmeterol/fluticasone propionate combination 50/100mcg BID delivered via Diskus or CFC - free metered dose inhaler (MDI) in children with asthma [Abstract]. European Respiratory Journal 2003;22(Suppl 45):Abstract No: [P1986].
122. Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centann S, et al.Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research & Opinion 2004;20(9):1403-1418 (Pubitemid 39361344)
123. Selroos O, Lofroos AB, Pietinalho A, Riska H. Asthma control and steroid doses 5 years after early or delayed introduction of inhaled corticosteroids in asthma: A real-life study. Respiratory Medicine 2004;98(3):254-262 (Pubitemid 38262660)
124. Glaxo Smith Kline. A multicentre, randomised, double-blind, double-dummy, parallel-group study to establish equivalence of the salmeterol/ fluticasone propionate combination product (50/250 μg) via either the reservoir powder inhalation device (RPID) or via the Diskus Inhaler over 12 weeks in adolescents and adults with moderate asthma. Www.Clinicalstudyresults.Org 2004.
125. SFCF3002 (GSK). A multicentre, randomised, double-blind, double-dummy, parallel-group study to establish equivalence of the fluticasone propionate/salmeterol combination (FSC) product (100/50μg) via either the reservoir powder inhalation device (RPID) or via the Diskus inhaler over 12 weeks in children with asthma. www.clinicalstudyresults.org 2004.
126. Sienra-Monge JJL, Del Rio-Navarro BE, Alvarez-Amador M, Blandon-Vijil V, Gomez Chico-Velasco R. The Quality of Life of the Asthmatic Child Caregiver. Gaceta Medica De Mexico 2004;140(2): 139-145 (Pubitemid 38620399)
127. * Sorkness CA, Lemanske Jr RF, Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD, et al.Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial. Journal of Allergy & Clinical Immunology 2007;119(1):64-72.
128. Stelmach I, Grzelewski T, Jerzynska J, Kuna P. A randomized, double-blind trial on the effect of treatment with montelukast, budesonide, montelukast with budesonide, formoterol with budesonide on lung function and clinical symptoms in children with asthma [Abstract]. Journal of Allergy & Clinical Immunology 2005;115(2 Suppl):S151.
129. * Stelmach I, Grzelewski T, Majak P, Jerzynska J, Stelmach W, Kuna P. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. Journal of Allergy and Clinical Immunology 2007; Vol.Epub ahead of print (accessed 17th January 2008).
130. Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM, et al.A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respiratory Medicine 2004;98(11):1051-1062 (Pubitemid 39317934)
131. van den Toorn LM, Prins JB, de Jongste JC, Leman K, Mulder PG, Hoogsteden HC, Overbeek SE. Benefit from anti-inflammatory treatment during clinical remission of atopic asthma. Respiratory Medicine 2005;99(6):779-787 (Pubitemid 40631306)
132. Vogelmeier C, D'Urzo A, Pauwels R, Merino JM, Jaspal M, Boutet S, et al.Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?. European Respiratory Journal 2005;26(5):819-828 (Pubitemid 41632038)
133. Von Berg A, Papageorgiou Saxoni F, Wille S, Carrillo T, Kattamis C, Helms PJ. Efficacy and tolerability of formoterol turbuhaler in children. International Journal of Clinical Practice 2003;57(10):852-856. (Pubitemid 38088799)
134. Weiler JM, Nathan RA, Rupp NT, Kalberg CJ, Emmett A, Dorinsky PM. Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. Annals of Allergy, Asthma and Immunology 2005;94(1):65-72. (Pubitemid 40129638)
135. You-Ning L, Humphries M, Du X, Wang L, Jiang J. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. International Journal of Clinical Practice 2005;59(7):754-759 (Pubitemid 43904538)
136. Adams NP, Bestall JC, Malouf R, Lasserson TJ, Jones P. Beclomethasone versus placebo for chronic asthma. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD002738.Pub2]
137. Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003135.Pub4]
138. Adams NP, Bestall JC, Jones P, Lasserson TJ, Griffiths B, Cates CJ. Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003534.pub3]
139. Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, et al.Meta-analysis: Effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. www.annals.org (accessed 5th June 2008) 2008;149(1):Epub.
140. Bisgaard H. Effect of long-acting β2 agonists on exacerbation rates of asthma in children. Pediatric Pulmonology 2003;36:391-398 (Pubitemid 37296699)
141. British Thoracic Society. British Guideline on the Management of Asthma. BTS website www.brit-thoracic.org.uk 2007.
142. Becker A, Bérubé D, Chad Z, Dolovich M, Ducharme F, D'Urzo T, et al.Canadian Pediatric Asthma Consensus Guidelines, 2003 (updated to December 2004). Canadian Medical Association Journal 2005; Vol.173, issue 6 Suppl.
143. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006363.pub2]
144. Cates CJ, Lasserson TJ, Cates MJ. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD006924.pub2]
145. Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD006922.pub2]
146. Higgins JPT, Green S (editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008:Available from www.cochrane-handbook. org.
147. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-188
148. Ducharme F, Lasserson TJ, Cates CJ. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD003137.pub3]
149. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NIH Publication 2007:Available at: http: //www.ginasthma.com.
150. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(557):560.
151. Manning P, Gibson PG, Lasserson TJ. Ciclesonide versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD006217.Pub2] (Pubitemid 351824586)
152. National Asthma Council, Australia. Asthma Management Handbook. www.nationalasthma.org.au 2006.
153. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR 3) Guidelines for the Diagnosis and Management of Asthma. NIH Publication. Bethesda, MD: National Heart, Lung and Blood Institute, 2007:Available at: http: //www.nhlbi.nih.gov/guidelines/asthma/index.htm.
154. Sharek PJ, Bergman DA, Ducharme F. Beclomethasone for asthma in children: effects on linear growth. Cochrane Database of Systematic Reviews 1999, Issue 3. [DOI: 10.1002/1465]
155. Walters EH, Gibson PG, Lasserson TJ, Walters JAE. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database of Systematic Reviews 2007, Issue 1. [Art. No.: CD001385. DOI: 10.1002/14651858. CD001385.pub2]
156. Greenstone IR, Ni Chroinin MN, Masse V, Danish A, Magdalinos H, Zhang X, Ducharme FM. Combination of inhaled longacting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005533.]
157. MNi Chroinin, IR Greenstone, A Danish, H Magdolinos, V Masse, X Zhang, FMDucharme. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD005535.]